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In the interest of animal welfare, and in order that the results from animal trials are 
considered valid for inclusion in the development of regulations, it is necessary that 
such trials are undertaken in accordance with the appropriate licensing arrange-
ments. In January 2013, new licensing arrangements were introduced in the European 
Union. The aim of this paper is to outline the legislative strategy required for obtaining 
licences for animal trials and based on live animal trials with flukicides, establishes 
a blueprint for obtaining the appropriate licences and undertaking the experiments.   
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Introduction
When undertaking studies involving live 
animals, it is important that they are 
undertaken in accordance with approved 
legislative protocols. In that way, such 
studies are regulated and the results can 
provide data to inform decision-makers. 
This paper, based on the protocol for 
obtaining licenses and undertaking trials 
with veterinary drugs, attempts to set a 
benchmark for undertaking animal tri-
als and to give guidance on the proto-
cols that should be followed in research 
experimentation. 
The research question relates to the 
determination of the presence and rate of 
withdrawal of anthelmintic and antibac-
terial drugs in milk, following treatment 
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of live animals, and their transfer to a 
range of dairy products during the manu-
facturing process. The additional ques-
tions related to (i) the pasteurisation of 
milk and whether the pasteurisation pro-
cess results in significantly different resi-
due levels in dairy products compared to 
unpasteurised milk and (ii) whether the 
residues are stable during storage/ripen-
ing of the manufactured products and 
are stable when frozen. These research 
questions were addressed at each stage 
of the process for both milk and the milk 
products, which included; cheese, but-
ter and milk powder manufactured from 
the milk containing the analyte for each 
respective trial.  
What are Veterinary Drugs?
Veterinary drugs are pharmacologically 
active substances used in the prevention, 
diagnosis and treatment of disease, dis-
order and injury in animals (Stolker and 
Brinkman 2005). The use of veterinary 
drugs in the European Union (EU) is 
regulated by European Council regulation 
(EC No. 470/2009, EU No. 37/2010; Anon. 
2009; Anon 2010a). Regulation EC No. 
470/2009 describes the procedure for the 
establishment of maximum residue limits 
(MRLs). The MRL is the maximum con-
centration of residue accepted by the EU 
in a food product obtained from an animal 
that has received a veterinary medicine 
or that has been exposed to a biocidal 
product for use in animal husbandry. The 
EU requires by law that foodstuffs, such 
as meat, milk or eggs, obtained from ani-
mals treated with veterinary medicines or 
exposed to biocidal products used in ani-
mal husbandry must not contain any resi-
due that might represent a hazard to the 
health of the consumer. Regulation EC 
No. 470/2009 (Anon. 2009) describes the 
procedure for the establishment of MRLs.
The Annexes of regulation EU No. 
37/2010 (Anon. 2010a) present the follow-
ing information:
• Annex I includes substances for which 
final MRLs have been established;
• Annex II includes substances for which 
it is not considered necessary for the 
protection of public health to establish 
MRL values;
• Annex III includes substances with pro-
visional MRLs. This includes medicines 
for which MRLs can be established, but 
clarifications from additional research 
studies are required before final MRLs 
can be set; and
• Annex IV includes substances for which 
no MRL can be established as residues 
of these substances, at whatever limit, 
in foodstuffs of animal origin constitute 
a hazard to the health of the consumer. 
The products in this group are prohib-
ited for use in food producing animals 
in the EU.
No new medicine can be licensed or sold 
for use in food producing animals until 
its active ingredient(s) have been entered 
into Annexes I, II or III of Regulation 
EU No. 37/2010 (Anon. 2010a). In addi-
tion, Council Directive 96/23/EC (Anon. 
1996) specifically regulates control and 
monitoring of pharmacologically active 
compounds (Stolker and Brinkman 2005). 
Residues of such compounds are divided 
into Group A compounds, i.e. prohibited 
substances in conformity with Annex IV 
of Regulation EU No. 37/2010 (Anon. 
2010a) and Group B compounds, i.e. all 
registered veterinary medicines in confor-
mity with Annexes I and III of Regulation 
EU No. 37/2010.
MRLs and Public Health
In order to prevent unsafe levels of vet-
erinary drug residues from entering the 
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human food chain, the establishment of 
an MRL can lead to the setting of an 
appropriate withdrawal period for a par-
ticular medicine. The withdrawal period 
for milk is the period of time that must 
elapse between the last administration of 
a medicine and consumption or use of a 
foodstuff derived from the treated animal 
to which the medicine was administered. 
This period ensures that the level of resi-
due in a foodstuff is lower than the MRL 
and the foodstuff is therefore deemed 
safe for human consumption. Setting of 
an MRL and withdrawal period is a neces-
sary step for all licensed medicinal drugs 
administered to livestock that produce 
food for human consumption. These with-
drawal periods must be strictly observed 
(Veterinary Medicines Directorate [VMD] 
2008) and can vary depending on the 
route of administration, physicochemical 
properties of the drug, animal species and 
the type of food produced (Moreno et al. 
2005).
Antiparasitic medicines are widely used 
for the protection or treatment of ani-
mals against external and internal para-
sitic diseases (Rahman and Samad 2010; 
Whelan et al. 2010a). The study outlined 
in this paper related to depletion studies 
of anthelmintic medicines (active against 
internal parasites), specifically flukicides, 
in dairy cows, for example triclabenda-
zole, which has activity against mature 
and immature liver fluke. Triclabendazole 
belongs to the benzimidazole drug class 
and is widely used in both human and vet-
erinary medicine for the treatment of liver 
fluke (Fasciola hepatica, class Trematoda) 
infections (Alvarez et al. 2009). Other 
anthelmintics examined were closantel 
and rafoxanide. Both are broad spectrum 
salicylanilide anthelmintics (Yeung et al. 
2010) and are effective against mature 
and developmental stages of a number 
of hematophagous nematodes, trematodes 
and arthropods in sheep, goats and cattle 
(Michels, Meuldermanns and Heykants 
1987; Ghoneim et al. 2006). Closantel binds 
strongly to plasma proteins, which serves 
to prolong anthelmintic activity for up to 
28 days (Hennessy et al. 1993; Yeung et al. 
2010) and has been issued a provisional 
MRL until 2014 in animals producing milk 
for human consumption and has thus been 
added to Annex III of Regulation EU No. 
37/2010 (Anon. 2010a).
However, rafoxanide is currently not 
permitted for treatment of animals where 
the milk is intended for human consump-
tion due to lack of an MRL and milk 
withdrawal period. If sufficient data is 
generated on rafoxanide in the future, 
it also has the potential to be added to 
Annex III. 
In addition to anthelmintics, a single 
broad-spectrum antibiotic, florfenicol, was 
investigated. Florfenicol belongs to the 
same amphenicol pharmacological group 
as chloramphenicol (Schwarz et al. 2004; 
Ruiz et al. 2010) and is effective as a bac-
teriostatic antibacterial, preventing pro-
tein synthesis in bacterial cells (Atef et al. 
2010; Lim et al. 2010; Xie et al. 2011). 
However, while the mechanism of antibac-
terial activity is similar between florfenicol 
and chloramphenicol (Atef et al. 2010) 
as protein synthesis inhibitors (Sun et al. 
2004), florfenicol has superior antibacte-
rial activity (Ruiz et al. 2010) because of 
the presence of a fluorine atom making it 
resistant to deactivation by transmissible 
plasmids of bacteria (Ruiz et al. 2010). In 
addition, due to its lipophilicity, florfeni-
col demonstrates good tissue penetration 
(Schwarz et al. 2004) and is active against 
bovine respiratory disease (BRD) and 
many chloramphenicol-resistant bacterial 
strains (Atef et al. 2010). Due to its supe-
rior antibacterial activity, florfenicol is 
widely used in non-lactating cattle. It is 
not currently permitted for use in lactating 
188     IRISH JOURNAL OF AGRICULTURAL AND FOOD RESEARCH, VOL. 52, NO. 2, 2013
dairy cows but completion of studies on 
this antibiotic could lay the basis for its 
inclusion as a dairy animal medicine. 
The Need for Data in the establishment 
of MRLs 
There is a need for data to inform the 
European Medicines Agency’s Committee 
on Veterinary Medicinal Products in the 
establishment of MRLs of such products 
in milk. Some flukicides such as closantel, 
nitroxynil and triclabendazole which pre-
viously had no MRL for milk have recent-
ly been assigned provisional MRLs in 
milk by the European Medicines Agency’s 
Committee on Veterinary Medicinal 
Products (CVMP). As these are provi-
sional MRLs there is an obvious need 
for more data on the persistence of fluki-
cide residues in milk following treatment 
and on the migration of these medicines 
into milk-derived products. These pro-
visional MRLs, due to expire in January 
2014, were set for the flukicides; nitroxynil 
(Anon. 2012a), closantel (Anon. 2012b), 
triclabendazole (Anon. 2012c) and clor-
sulon (Anon. 2012d). The CVMP recom-
mended a two-year period to allow for the 
completion of scientific studies on these 
four flukicides. There was insufficient data 
in order to set a provisional MRL for 
rafoxanide.  
Animal Welfare – Licensed Trials
In Ireland, the use of animals for experi-
mental purposes has been controlled 
using a statute enabled in 1876 Cruelty 
to Animals Act (Government of Ireland 
1876; [Anon. 1876]), which has been subse-
quently amended by Statutory Instrument 
(SI) 566/2002 (Anon. 2002). This required 
that any person wishing to use an animal 
for a scientific purpose must have an 
authorisation (a license) issued by the 
Minister for Health and Children. Prior 
to the 2002 amendment of the Cruelty 
to Animals Act by S.I. 566/2002 (Anon. 
2002), the European Council of Ministers 
adopted Directive 86/609/EEC (Anon. 
1986) on ‘the protection of animals used 
for experimental and other scientific pur-
poses’. It was recently decided however, 
that the European Directive concerning 
the use of animals in research should be 
revised and 2010/63/EU (Anon. 2010b) 
was applied across the EU from 1st January 
2013. This Directive was transposed into 
Irish law by SI No. 543 of 2012 (Anon. 
2012e). From January 1st 2013, the Irish 
Medicines Board (Anon. 2012e) became 
the competent authority responsible for 
the implementation of Directive 2010/63/
EU on the protection of animals used for 
scientific purposes in accordance with the 
requirements of SI No 543 of 2012 (Anon, 
2012e). 
Old Licensing System
Directive 86/609/EEC (Anon. 1986) 
sought to improve the controls on the use 
of laboratory animals and set minimum 
standards for housing and for the training 
of personnel in handling animals for sci-
entific purposes. In addition, the Directive 
involved the supervision of animal experi-
ments with the objective of reducing the 
numbers of animals used for experimen-
tation by: (i) requiring that an animal 
experiment should not be performed if 
an alternative method existed and (ii) by 
encouraging the development and vali-
dation of alternative methods to replace 
animal methods. The Directive envisaged 
that most experiments would be carried 
out while the animal was under anesthetic 
and that it would not be allowed to recover 
from that state, i.e. the animal would be 
euthanised. However, it was recognised 
that there would be instances where the 
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immediate death of the animal would frus-
trate the aims of the experiment. In such 
cases, there was provision within the Act 
for the granting of certificates (or exemp-
tions), such as:
• Certificate A – permitted the worker 
to dispense with anaesthesia where the 
minimum amount of pain was envis-
aged. (This was the exemption sought 
and granted for use in the trials in this 
current study);
• Certificate B – permitted an animal to 
recover from an anaesthetic where the 
post-procedural care of the animal was 
required to be given in detail in order to 
acquire the certificate;
• Certificate C – permitted the use of ani-
mals in the teaching of students; 
• Certificate D – necessary if the ani-
mal could potentially experience severe 
pain that was likely to be prolonged;
• Certificates E, EE & F – necessary if 
dogs, cats or equines were to be used as 
experimental animals; and
• Certificate G – necessary whenever the 
setting-free of the animal was necessary 
for the legitimate purposes of the pro-
posed experiment.
In addition to the license and certifi-
cate required, the Minister of Health and 
Children also required two prominent 
members of society, for example, a pro-
fessor of surgery/medicine or a medical 
practitioner to add their approval to the 
licence. These signatories were required 
to certify that the aim of the project was 
worthwhile and could not be produced by 
anaesthetics without necessarily under-
mining the objective of the experiment.
As a standard condition, it was required 
that the experiments were performed at a 
registered place approved by the Minister 
of Health and Children. Registered 
places were visited by inspectors from 
time to time for the purpose of ensuring 
compliance with the Cruelty to Animals 
Act 1876 (Anon. 1876). Licensees were 
required to keep a written record of their 
experiment(s), sending a “return” of the 
number and nature of the experiments(s) 
performed during the year to the 
Department of Agriculture, Food and the 
Marine (DAFM) BioResources Services 
(Trinity College Dublin 2012). The licence 
number obtained from the Department 
of Health and Children in 2011 to enable 
completion of trials for this study was Ref: 
B100/4375 Expiry Date 19th December 
2015. All trials in the current study were 
completed prior to the change in legisla-
tion. Therefore, the requirements under 
the Department of Health and Children 
and DAFM applied.
Animal Remedies License
In addition to the experimentation licens-
ing requirement, research involving the 
use of unlicensed medicines requires a 
license from DAFM. The application to 
DAFM includes details of the veterinary 
medicine proposed for administration, 
information on the type of animal that is 
to be used for each trial and identifica-
tion of the people involved in ensuring 
the welfare of trial animals, including 
the experimental license authorisation 
number for each person. It is impera-
tive that this application indicates that 
the trial will be conducted in accordance 
with the International Cooperation on 
Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal 
Products guidelines on good clinical prac-
tice (VICH GL9 on GCP) of June 2000 (as 
implemented in July 2001). Compliance 
with these guidelines provides assurance 
regarding the integrity of trial data and 
that animal welfare is guaranteed through-
out the entirety of the trial. Compliance 
with manufacturers’ guidelines regarding 
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appropriate dosage procedures for the 
veterinary drug to be administered must 
be included in each license application. 
Finally, the procedure to be followed in 
cases where the trial animal develops an 
adverse reaction to the administered drug 
must be specified. 
In the trials conducted in this cur-
rent study, milk samples were taken from 
the trial animals following drug admin-
istration until residues had depleted to 
undetectable levels. The license numbers 
obtained from DAFM for each trial con-
ducted in this study were as follows:
• DAFM License No. RL/10/03 for lac-
tating trial for triclabendazole, closan-
tel and rafoxanide (valid from 28/1/11 
to 27/1/12);
• DAFM License No. RL/11/03 for lac-
tating trial for florfenicol (valid from 
8/8/11 to 7/8/12); and
• DAFM License No. RL/10/03A for 
dry period closantel trial (valid from 
1/11/11 to 30/6/12).
New Licensing System
Under the new Directive 2010/63/EU 
(Anon. 2010b), each establishment which 
breeds, supplies or uses animals intended 
for scientific purposes must have an inter-
nal animal welfare body. This is in accor-
dance with Article 26 of Directive 2010/63/
EU and Regulation 50 of SI No. 543 of 
2012 (Anon. 2012e), where the individu-
als responsible for the welfare and care 
of animals within each establishment are 
required to be a member of the animal 
welfare body. 
The animal welfare body is required 
to consist of at least one person respon-
sible for the welfare and care of animals 
and in the case of a user establishment, 
at least one member of the scientific 
workforce. Therefore, in practice, there 
must be at least two members from each 
establishment on the animal welfare body. 
The de signated veterinarian or suitably 
qualified expert may or may not be a 
member also, but in any case must provide 
input to the animal welfare body. The 
duties of the animal welfare body are set 
out in Article 27 of Directive 2010/63/
EU (Anon. 2010b). Information on each 
member appointed to the animal welfare 
body is expected to be provided with a 
clear outline of their role in that body. In 
some establishments, the animal welfare 
body may be linked to the ethics commit-
tee of the establishment. If this is the case, 
the relationship between the two bodies is 
required to be described in the site master 
file in accordance with Regulation 36(2) 
of SI No. 543 of 2012 (Anon. 2012e) which 
contains information about the main activ-
ities carried out at the designated site, the 
quality management system in operation 
at the site and the lines of control and 
responsibilities exercised by the personnel 
at the site.
Directive 2010/63/EU (Anon. 2010b) 
lays down specific requirements for per-
sonnel involved in various procedures at 
the establishment through Articles 20(2), 
24 and 25. Details on each of the respon-
sible personnel in the establishment must 
therefore be provided, specifically:
• Compliance officer: the person respon-
sible for compliance of the establish-
ment with the provisions of Article 
20(2) of Directive 2010/63/EU (Anon. 
2010b) and Regulation 44 of S.I. No. 
543 of 2012 (Anon. 2012e);
• Animal care and welfare officer: the 
person responsible for overseeing the 
welfare and care of the animals at 
the establishment (Article 24 [1a] of 
Directive 2010/63/EU and Regulation 
45 of S.I. No. 543 of 2012);
• Training officer: the person respon-
sible for ensuring that the staff are 
adequately educated, competent and 
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continuously trained in animal care and 
handling and that they are supervised 
until they have demonstrated the req-
uisite competence (Article 24[1c] of 
Directive 2010/63/EU and Regulation 
46 of S.I. No. 543 of 2012); and
• The designated veterinarian or suit-
ably qualified expert in accordance with 
Article 25 of Directive 2010/63/EU and 
Regulation 48 of S.I. No. 543 of 2012.
The documentation on the monitoring of 
the health and welfare of animals at the 
establishment is required which includes 
the following: (i) the maintenance of ani-
mal records including records of animal 
mortality and (ii) ensuring the compliance 
with any standard operating procedures 
for the conducting of procedures and / or 
euthanasia in animals, including animal 
statistics on the use of animals in proce-
dures and on the actual severity of the 
procedures. This documentation must be 
generated and returned to the competent 
authority on an annual basis (in accor-
dance with Article 54). This informa-
tion is mandatory. Once an establishment 
authorisation is granted the establishment 
is licensed for a maximum period of 3 
years, as opposed to 5 years under the 
Department of Health and Children and 
is subject to renewal thereafter. 
Each individual involved in perform-
ing experimental procedures on animals 
must be individually authorised by the 
Irish Medicines Board (IMB) before 
conducting any procedures. Individual 
authorisation is obtained by submission 
of the relevant form, a CV and training 
record. Overall project authorisation can 
be applied for using the relevant forms, 
which involves submission of a technical 
and non-technical version of the proj-
ect proposal. Approval of each project 
by the research institutions’ ethics com-
mittee must also be submitted with the 
application, unless an explanation can 
be provided as to why it has not been 
included. Finally, a request for experiment 
classification can be submitted in order to 
determine if a full experimental proposal 
application is required. Again, the rele-
vant form is available from the IMB. A 
summary of current licensing procedures 
is included in Figure 1.
Experimental Design
Lactating cow trials
For triclabendazole, rafoxanide, closantel 
and florfenicol, four separate in vivo trials, 
where the drugs were administered indi-
vidually, were conducted in the lactating 
period to ascertain the withdrawal period 
Application for
authorisation of
research
establishment
Application for
authorisation of
individual(s)
completing the
research 
Application for
authorisation of
experiment -
Technical & non-
technical version
Request for
experiment
classification
Figure 1. Summary of the new IMB experimental licensing procedures.
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for each analyte. A total of six lactating 
dairy cows (Friesian, n = 3; Montbeliard, 
n = 2; Norwegian Red, n = 1) were 
assigned to the experiment. For each of 
the four trials, the six cows were divided 
into two groups of three cows (balanced 
by breed as much as possible) and the 
total milk from each group was collected 
and pooled on days 2 and 23, which should 
be representative of high and low residue 
concentrations, respectively. Each milk 
pool was further sub-divided into two; 
one portion was pasteurised (72 °C×15 s) 
while the second remained unpasteurised, 
resulting in eight portions of milk for each 
of the four lactating cow trials. For further 
detail on the experimental procedure, see 
Power et al. (2013a). 
Milk studies Following treatment, milk 
samples were taken twice daily (morning 
and evening) up to day 23 post-administra-
tion for the triclabendazole trial. For the 
closantel trial, milk samples were taken 
twice daily (morning and evening) up to 
day 59 (when concentrations were below 
the MRL) and subsequently samples were 
collected weekly until day 199 post-treat-
ment. The rafoxanide trial required milk 
samples to be taken twice daily up to day 
68 post-administration and for the florfen-
icol trial, milk samples were taken twice 
daily up to day 28 post-administration 
until no respective analyte was detected 
in the milk. Samples were labeled on col-
lection and stored at –20 °C and analysed 
within one week of collection for each of 
the four trials. Since it was necessary to 
use the same six cows for all trials and as 
low residual concentrations of closantel 
remained for 199 days, it was necessary to 
begin the rafoxanide trial at day 63 when 
the closantel concentration was below 
the provisional MRL of 45 µg/kg for all six 
cows. This did not interfere with the detec-
tion of either compound.
Product studies From each portion of milk, 
a semi-soft laboratory scale cheese was 
manufactured and the remainder of the 
portion was separated into skim-milk and 
cream. After separation of the curd and 
whey during cheesemaking, both were ana-
lysed in addition to the final cheese. Butter 
and buttermilk were manufactured from 
the cream and skim-milk powder was manu-
factured from the skim-milk (Figure 2). 
Stability studies For all trials, samples 
were studied by analysing fresh product 
on the day of manu facture, freezing it at 
–20 °C and analysing the samples again 
after 6 and 12 months. Furthermore, after 
each weekly sample of cheese or butter 
had been analysed, the remaining portion 
of each sample was frozen at –20 °C for 
further residue analysis at 6 and 12 months. 
Skim milk powder was stored in 50 mL cen-
trifuge tubes in the dark at ambient tem-
perature (18–22 °C). Samples of powder 
were taken at day 0 and at 6 and 12 months 
and analysed for the presence of residues.  
Dry-cow trials 
For the dry period closantel trial, closantel 
was administered to the same six cows prior 
to drying off, at the end of lactation. Milk 
samples were taken from each individual 
cow following calving for up to 189 days 
post-administration, when residue could 
be no longer detected in the milk sampled 
from any of the six trialed animals.
Replicates
Since individual cows will metabolise vet-
erinary drugs at a different rate, it is 
necessary to monitor drug depletion in 
the individual cows. Therefore, the milk 
from each of the six cows was analysed 
independently.
Product manufacture 
Trials with triclabendazole, closantel, 
rafoxanide and florfenicol analytes (at 
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high and low residue concentrations) were 
undertaken in independent duplicate, with 
products being manufactured from two 
separate pools of milk from grouped ani-
mals (Figure 2). In addition, product was 
made from both pasteurised and unpas-
teurised milk, resulting in four indepen-
dent analyses (two with pasteurised milk 
and two with unpasteurised milk). 
Validation and analyses
Residue analysis of the samples was 
undertaken by Ultra High Performance 
Liquid Chromatography – Tandem Mass 
Spectrometry UHPLC-MS/MS (Whelan 
et al. 2010b). The validation of the analy-
ses in milk was carried out by fortifying 
negative bovine, caprine and ovine milk 
samples at 0.5, 1.0 and 1.5 times the provi-
sional MRL (n = 7 at each level) for mea-
surement of triclabendazole, rafoxanide, 
closantel and florfenicol.
The dairy product validations were car-
ried out by fortifying negative controls 
(butter manufactured from bovine milk, 
cheeses manufactured from bovine, cap-
rine and ovine milk and skimmed milk 
powder and infant formula manufactured 
from bovine milk) at differing concentra-
tions (n = 7 at each level) for each analyte. 
The results of the experiments undertaken 
have been published elsewhere (Power 
et al. 2012; 2013a,b,c,d).
Study Animals Post-Experimentation
As per the licensing agreement, milk from 
the six animals was added to the slurry 
tank and spread as slurry. The six animals 
were slaughtered on 13th December 2012, 
in excess of one year after the final admin-
istration of a veterinary medicine. 
Summary
This protocol sets out the licensing and 
documentation requirements for live 
animal trials in terms of animal welfare 
Complete
milk yield
Pooled
group 1
Pooled
group 2
Whey
Cheese
Pasteurised
milk 2
Raw milk
1
Whey
Cheese
Curd
Curd
SkimCream
Butter
Buttermilk
Powder
Cream Skim
Butter
Buttermilk
Powder
Raw milk
3
Cheese Cream Skim
Curd
Pasteurised
milk 4
Cheese
Butter Powder
Whey Buttermilk
Cream Skim
Curd Butter Powder
Whey Buttermilk
Figure 2. Flowchart of the process of product manufacture from milk for each analyte being 
trialed. This flow chart was followed for each of the 4 residues at high and low concentra-
tions. Reprinted with permission from Power et al. (2013b). Copyright (2013) American 
Chemical Society.
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(housing and management), person-
nel conducting the work and the use of 
trial substances. A protocol such as that 
described here is important in that it is a 
good guideline to follow when undertak-
ing licensed trials involving Department 
regulators. 
The project was undertaken in 
Teagasc and represented a collabora-
tive work involving the Teagasc Animal 
and Grassland Research and Innovation 
Centre in Fermoy, Co. Cork, (AGRIC), 
where animals were treated, the Teagasc 
Food Research Centre, Fermoy, Co. Cork 
(TFRCM), where product was manufac-
tured, and the Teagasc Food Research 
Centre, Ashtown, Dublin (TFRCA), where 
analyses were undertaken, with supervi-
sion from Cork Institute of Technology.
All animal trials for each veterinary drug 
under investigation were fully licensed 
by both the Department of Health and 
Children and DAFM according to pre-
2013 experimental license guidelines. A 
new licensing system for experimentation 
using animals came into effect on January 
1st 2013.
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